6883

RemeGen Co. Ltd. A

688331.SHG remegen.com + Research + Basket
ISIN CNE100005B03
Employees 3,048
Phone 86 53 5611 3511
Fiscal year end December
Address 58 Middle Beijing Road, Yantai, China
95.20
-2.01 (-2.07%)
CNY · SHG
52-week range
75.03
157.80
Trading at 24% of the 52-week range
Market Cap
53.71B
P/E Ratio
9.15
Forward P/E
0.00
Book Value
15.87
Div. Yield
N/A
% Institutions
11.66%
% Insiders
54.12%

1 Year

+5.1%

3 Year

+40.0%

10 Year

+133.1%
Description

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.

Actions

Add an action for 688331.SHG, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Weidong Wang Co-Founder & Executive Chairman 1959
Dr. Jianmin Fang Co-Founder, CEO, GM, Member of Scientific Advisory Board & Executive Director 1962
Mr. Shaojing Tong CFO & Company Secretary 1971
Mr. Qingkai Wen Executive Director & Board Secretary 1966
Mr. Kaisheng Huang Chief Operating Officer NA
Jian Liang Wei Accounting Supervisor NA
Dr. Marie Zhu Chief Technical Officer NA
Dr. Xiaoming Yang Ph.D. Chief Manufacturing Officer 1964
Dr. Ming Shi M.D., Ph.D. Chief Medical Officer 1967
Ms. Yi Fang Executive Director NA

Financial Highlights

▼
Market Cap: $53.71B
EBITDA: $5.32B
P/E Ratio: $9.15
Book Value: $15.87
Earnings/Share: $10.41
Profit Margin: 78.77%
Operating Margin: 7.75%
ROA (TTM): 38.23%
ROE (TTM): 116.54%
Revenue (TTM): $8.29B
Revenue/Share (TTM): $14.77
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 46.40%

Valuation Metrics

Enterprise Value: $41.03B
Trailing P/E: 9.15
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 355.64M
Shares Float: 346.65M
% Insiders: 54.12%
% Institutions: 11.66%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$3.25B
Cost of Goods Sold
adjust
$-425.51M
Gross Profit
subtotal
$3.25B
SG&A
adjust
$-1.47B
R&D
adjust
$-1.22B
Operating Income
subtotal
$721.43M
Other / Non-Operating Items
adjust
$-12.91M
Net Income
subtotal
$708.52M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about 688331.SHG!